Nov 2017: diagnosed with Stage IV, High-Risk Neuroblastoma; Nov 2017-April 2019: completed standard treatment protocol / no evidence of disease (NED); April 2019-April 2021: enrolled in/completed DFMO clinical trial; April 2022: RELAPSE; April 2022-June 2023: completed relapse treatment protocol / NED (again); June 2023-June 2024: enrolled in “compassionate use” high-dose DFMO clinical trial; June 2024: RELAPSE #2; July 2025 NED (again)
Thursday, January 4, 2024
Friday, November 24, 2023
Sunday, October 1, 2023
Friday, June 30, 2023
Wednesday, June 21, 2023
Saturday, June 17, 2023
Monday, June 12, 2023
Monday, May 29, 2023
Tuesday, May 23, 2023
Thursday, May 11, 2023
Wednesday, May 3, 2023
Thursday, April 20, 2023
Saturday, April 8, 2023
Tuesday, April 4, 2023
Sunday, March 19, 2023
Monday, March 13, 2023
Sunday, February 26, 2023